Decibel Therapeutics to Present at the Jefferies Gene Therapy/Editing Summit

Rhea-AI Summary

Decibel Therapeutics (Nasdaq: DBTX) announced that its CEO, Laurence Reid, will participate in a fireside chat at the Jefferies Gene Therapy/Editing Summit on October 27, 2021, at 10:30 am ET. The session will be available for live streaming on Decibel’s website, with an archived replay accessible for 90 days post-event. Decibel is focused on innovative treatments for hearing and balance disorders and has a promising pipeline, including the lead program DB-OTO, targeting congenital hearing loss.

BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in a fireside chat at the Jefferies Gene Therapy/Editing Summit on Wednesday, October 27, 2021 at 10:30 am ET.

A live webcast of the fireside chat may be accessed by visiting the Investors section of the Decibel Therapeutics website at https://ir.decibeltx.com. An archived replay of the webcast will be available on the Company’s website for approximately 90 days following the fireside chat.

About Decibel Therapeutics

Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of creating a world of connection for people with hearing and balance disorders. For more information about Decibel Therapeutics, please visit www.decibeltx.com or follow us on Twitter.

Investor Contact:
Julie Seidel
Stern Investor Relations, Inc.
julie.seidel@sternir.com
212-362-1200

Media Contact:
Chris Railey
Ten Bridge Communications
Chris@tenbridgecommunications.com
617-834-0936

FAQ

What is Decibel Therapeutics' upcoming event on October 27, 2021?

Decibel Therapeutics will have its CEO, Laurence Reid, speak at the Jefferies Gene Therapy/Editing Summit at 10:30 am ET.

Where can I watch the Decibel Therapeutics fireside chat?

The fireside chat can be accessed live on Decibel Therapeutics' website in the Investors section.

What is DB-OTO?

DB-OTO is Decibel Therapeutics' lead gene therapy program designed to treat congenital, monogenic hearing loss.

What is the focus of Decibel Therapeutics?

Decibel Therapeutics is focused on developing transformative treatments for hearing and balance disorders.

How long will the webcast of the fireside chat be available?

The archived replay of the webcast will be available for approximately 90 days after the event.